Mn Services Vermogensbeheer B.V. Has $29.72 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Mn Services Vermogensbeheer B.V. raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 1st quarter, HoldingsChannel reports. The fund owned 95,392 shares of the medical research company’s stock after acquiring an additional 900 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Amgen were worth $29,719,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of AMGN. HT Partners LLC acquired a new position in shares of Amgen during the first quarter worth $214,000. Morton Capital Management LLC CA raised its position in Amgen by 10.2% during the 1st quarter. Morton Capital Management LLC CA now owns 6,478 shares of the medical research company’s stock worth $2,018,000 after purchasing an additional 598 shares during the last quarter. Optas LLC raised its position in Amgen by 15.3% during the 1st quarter. Optas LLC now owns 1,361 shares of the medical research company’s stock worth $424,000 after purchasing an additional 181 shares during the last quarter. Brighton Jones LLC lifted its holdings in Amgen by 5.6% during the 1st quarter. Brighton Jones LLC now owns 29,000 shares of the medical research company’s stock worth $9,035,000 after buying an additional 1,532 shares during the period. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH grew its position in shares of Amgen by 5,580.2% in the 1st quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 41,238 shares of the medical research company’s stock valued at $12,848,000 after buying an additional 40,512 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 0.7%

Shares of NASDAQ:AMGN opened at $295.22 on Friday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The business’s 50 day simple moving average is $281.33 and its two-hundred day simple moving average is $285.62. The firm has a market cap of $158.74 billion, a P/E ratio of 39.10, a PEG ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. During the same period last year, the business earned $3.96 EPS. Amgen’s quarterly revenue was up 9.4% compared to the same quarter last year. As a group, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on AMGN shares. Bank of America increased their price target on Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a research note on Wednesday, March 5th. Royal Bank of Canada decreased their target price on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Erste Group Bank lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. UBS Group reiterated a “neutral” rating and set a $315.00 price objective (down from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 18th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $309.22.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the firm’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now directly owns 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.76% of the stock is currently owned by company insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.